Comparative study of 99Tc-MDP and zoledronic acid in the treatment of osteoporosis

• 作者: Chao-Qun Wang Huan Xiao Juan-Juan Yan Quan Xie Wei-Min Pan Wei-Wen Yan Wen Sun Ying Huang Ying Zhou
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2020,（16）
• 页码范围: 35-39
• 页数: 5页
• 语种: 英文

摘要

Objective: To compare the efficacy and mechanism of zoledronic acid and Tc-MDP in the treatment of osteoporosis. Methods: From July 2011 to November 2015, 232 patients with primary osteoporosis were selected and treated in The First Affiliated Hospital of Hainan Medical College were selected and were divided into the 116 patients in the Tc-MDP group and 116 patients in the zoledronic acid group accorded to the treatment ways. The zoledronic acid group were given zoledronic acid treatment, 1 time in one year. The Tc-MDP group were given Tc-MDP treatment, and the treatment were treated for 10 days for 1 course, 1 course for 3 months, and a total of 3 years of treatment were observed. The prognosis and the changes of bone mineral density and hematological parameters were recorded. Results: The total effective rates of the zoledronic acid group and Tc-MDP group were 99.1％ and 90.0％, respectively, and the zoledronic acid group were significantly higher than the Tc-MDP group (P<0.05). The bone mineral density of lumbar vertebrae and hip after treatment were significantly higher than that of the two groups before treatment, and the zoledronic acid group were also significantly higher than the Tc-MDP group(P<0.05). The joint tenderness scores of the two groups were significantly lower than those before treatment, and the Tc-MDP group were also significantly lower than the zoledronic acid group (P<0.05). There were no significant differences in serum calcium and blood phosphorus levels compared between the two groups (P>0.05), and the erythroeyte sedimentation rate (ESR) levels were lower than before treatment (P<0.05), The ESR levels of the Tc-MDP group were also significantly lower than that of the zoledronic acid group (P<0.05). Conclusion: The zoledronic acid and the application of Tc-MDP in the treatment of osteoporosis can increase bone density, relieve joint tenderness symptoms, reduce ESR content, and will not affect patients' blood calcium and blood phosphorus levels. However, zoledronic acid increases bone density significantly are better than the Yunke, and Yunke relieves joint pain significantly are more than zoledronic acid.